Customized Choice of Oral P2Y12 Receptor Blocker

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

A subset of patients recruited in the main MATRIX study will be randomized after intervention but before discharge to standard of care (the treating physician will decide which oral P2Y12 inhibitor will be added on top of aspirin) versus a customized approach based on an algorithm which integrates phenotypic information, including but not limited to residual on-treatment platelet reactivity assessed via VerifyNow P2Y12 Assay.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Italian Society of Invasive Cardiology
• Collaborator: Eustrategy
• Treatments: Clopidogrel; Prasugrel Hydrochloride; Ticagrelor

Criteria

Inclusion Criteria:

• patients recruited in the main MATRIX study who underwent coronary angioplasty with stent placement.

Exclusion Criteria:

• unwillingness to sign this sub study specific informed consent